Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOMIC-III: PDT on Inguinal Skin Microbiome
NCT05676801Phase 1Unknown
- Sponsor
- University of Zurich
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methyl aminolevulinate in surgical site infection (SSI) and prosthetic joint infection (PJI), sponsored by University of Zurich. Primary endpoint: Culture results of skin swabs at Day 3. Status: unknown.
02
Drugs
methyl aminolevulinate
03
Conditions
surgical site infection (SSI)prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05676801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676801.